News
2d
Stocktwits on MSNPfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain AntibodiesPfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...
Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
8d
24/7 Wall St. on MSNIs It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth PotentialPfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results